Startups
Categories: BioTechFirmHardwareHealthTechMedtechMessangerProductPublicServiceTechnology
LaVoieHealthScience is a leading strategic, integrated communications firm, staffed with specialized
Likes
122
Followers
2.91K
Mentions
196
Overview
Location
United States, Massachusetts, Boston
Employees
11-50
Phone
+1 617-374-8800
Founded date
2001
Mentions in press and media 196
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 7, 2025 | Deciphex Secures $32.3M Series C to Address Global Pathology Shortage | DUBLIN–(BUSINESS WIRE)–January 7, 2025– Deciphex, a leader in AI-powered digital pathology, has closed its Series C financing, raising $32.3 million to address the acute global pathology crisis. Led by Molten Ventures with significant parti... |
| Dec 12, 2024 | Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines | The company will file the NDA for BRIMOCHOL™ PF, a once-a-day eye drop for the treatment of presbyopia, with a goal of US commercial launch in 1H, 2026 Merger initiates Crossover Financing Round with participation from syndicate members inc... |
| Jul 25, 2024 | GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment** ** | ** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round.... |
| Jul 19, 2024 | GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology | Proceeds to advance clinical development of lead program for gout, broaden the Company’s pipeline, and expand its genomically recoded organism platform BOSTON–(BUSINESS WIRE)–July 19, 2024– GRO Biosciences Inc. (“GRObio”), a biotechnology c... |
| Nov 2, 2023 | FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platform | Toku’s AI (CLAiR) technology platform has received FDA Breakthrough Device status, and if cleared by the FDA will deliver real-time cardiovascular disease (CVD) risk assessments through routine eye exams. FDA’s Breakthrough Device designati... |
| Oct 25, 2023 | To Moonshot, Or Not To Moonshot, Your Business? | Does your business have "moonshot" potential?Sasin Paraksa, Getty Images |
| Sep 27, 2023 | GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies | – Data represent promising new modalities for reversing autoimmune disease without immunosuppression and for eliminating anti-drug antibodies against immunogenic therapies BOSTON–(BUSINESS WIRE)–September 27, 2023– GRO Biosciences Inc. (“GR... |
| Sep 8, 2023 | Visus Therapeutics to Present at the Baird 2023 Global Healthcare Conference | SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)–September 8, 2023– Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, ... |
| May 4, 2023 | Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023 | BRIMOCHOL™ PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no significant adverse events. BRIMOCHOL™ PF achie... |
| Apr 20, 2023 | Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia | BRIMOCHOL PF, a preservative-free eyedrop, successfully met the pre-specified visual acuity primary endpoints for both the US and EU/UK against its active comparators carbachol and brimonidine. BRIMOCHOL PF successfully demonstrated “contri... |
| Mar 2, 2023 | Visus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care Conference | Topline Phase 3 data for best-in-class presbyopia candidate anticipated in 1H 2023 Non-surgical drug candidate to reverse cataracts expected to advance into clinical development in 2023 SEATTLE–(BUSINESS WIRE)–March 2, 2023– Visus Therapeut... |
| Jan 10, 2023 | Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023 | SAN FRANCISCO, Jan. 10, 2023 /PRNewswire/ -- Complete Genomics Inc (https://completegenomics.mgiamericas.com/), a subsidiary of MGI Tech Co., Ltd. ("MGI"), today unveiled its full sequencing platforms at Biotech Showcase during JP... |
| Dec 27, 2022 | Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer | Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today anno... |
| Dec 9, 2022 | Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma | Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing in patients following failure of conventional treatment |
| Nov 23, 2022 | AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference | Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s disease New data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity of ACI-35 and JACI-35, ... |
| Nov 3, 2022 | Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million | Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures Equity Funding led by CR-CP Life Science Fund, New Science Ventures, Fund+ and SRIW MONT SAINT-GUIBERT, ... |
| Oct 28, 2022 | AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update | Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome Received regulatory clearance to initiate an ada... |
| Oct 28, 2022 | AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update | Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome Received regulatory clearance to initiate an ada... |
| Oct 4, 2022 | AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome | Interim analysis expected around year-end 2022, informing Phase 2 start Trial progressing with regulatory clearances in the UK and also now in Spain Planned submission of U.S. Investigational New Drug application in Q1 2023 Continues progre... |
| Oct 4, 2022 | AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome | Interim analysis expected around year-end 2022, informing Phase 2 start Trial progressing with regulatory clearances in the UK and also now in Spain Planned submission of U.S. Investigational New Drug application in Q1 2023 Continues progre... |
| Sep 26, 2022 | AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease | AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26,... |
| Sep 1, 2022 | AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent | Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from ... |
| Aug 24, 2022 | AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases | Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities Integrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-... |
| Aug 11, 2022 | AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases | Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug... |
| Aug 2, 2022 | Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC | Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, multiple secondary... |
| Jul 28, 2022 | AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update | Three clinical readouts delivered year to date; four more expected by year-end First patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrom... |
| Jul 22, 2022 | AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference | New data from the API ADAD Study to be presented in AAIC Focused Topic Session New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease First-time presentation of innovative biomarker-based ... |
| Jun 24, 2022 | AC Immune Holds Annual General Meeting of Shareholders | LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual ... |
| Jun 16, 2022 | AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease | Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences favouring crenezumab over placebo were observed a... |
| Jun 9, 2022 | binx health CEO, Jeffrey Luber Announced as an EY Entrepreneur Of The Year 2022® New England Award Winner | BOSTON–(BUSINESS WIRE)–June 9, 2022– Ernst & Young LLP (EY US) today announced that Jeffrey Luber, Chief Executive Officer of binx health, was named an Entrepreneur Of The Year® 2022 New England Award winner. Entrepreneur Of The Year® i... |
| May 31, 2022 | AC Immune to Present at the 2022 Jefferies Healthcare Conference | LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will parti... |
| May 17, 2022 | AC Immune CEO Andrea Pfeifer Receives Aenne Burda Award | LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Dr. Andrea Pfeifer, CEO and a... |
| May 11, 2022 | Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia | Collaboration expands access to long-acting, presbyopia-correcting eye drops for approximately 600 million patients Visus to receive upfront payment of $15 million and up to $115 million in potential regulatory and commercial milestone paym... |
| May 9, 2022 | AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology | First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized formulation of the ACI-24 vaccine to e... |
| Apr 28, 2022 | AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update | Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine First images of alph... |
| Apr 27, 2022 | AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference | LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will par... |
| Apr 8, 2022 | AC Immune Reports Changes to Senior Management | Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO Julian Snow promoted to Vice President, U.S... |
| Mar 30, 2022 | AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases | a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated Morphomer® discovery technology platform in developi... |
| Mar 22, 2022 | AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update | Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta... |
| Mar 21, 2022 | AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases | LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key opinion leader (KOL)... |
| Mar 16, 2022 | AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference | ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson’s disease, Lewy Body Dementia, MSA and o... |
| Mar 16, 2022 | Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies | - Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce's advanced therapies drug development capabilities - HANGZHOU, China and ROCKVILLE, Md., March 16, 2022 /PRNewswire/ -- Innoforce, a global development and bi... |
| Feb 28, 2022 | AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs | Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies LAUSANNE, Switze... |
| Feb 15, 2022 | AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort | Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or high-dose cohorts to da... |
| Feb 4, 2022 | AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease | Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates Data further support advancing optimized ACI-24 into the next stag... |
| Feb 2, 2022 | AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference | LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will part... |
| Jan 25, 2022 | Dr. Philip Krause to Provide Strategic Advice to Adjuvance | Former FDA official will provide strategic consulting on scientific, regulatory and vaccine development matters LINCOLN, Neb.–(BUSINESS WIRE)–January 25, 2022– Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical c... |
| Jan 7, 2022 | Adjuvance Technologies Announces Issuance of U.S. Patent Covering Semi-Synthetic Saponin Adjuvants | Patent Covers TQL-1055 Adjuvant for Multiple Uses, Including Shingles Vaccine Protects the Foundation of the Company’s Proprietary Adjuvant Technology LINCOLN, Neb.–(BUSINESS WIRE)–January 7, 2022– Adjuvance Technologies Inc., a privately-h... |
| Dec 15, 2021 | AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs | Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD) Programs targeting intracellular disease mechanisms complemen... |
| Nov 30, 2021 | Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia | Three Proprietary Formulations Achieved a Three-Line Improvement in Binocular Near Visual Acuity, without Losing One Line in Distance Visual Acuity with a Minimum Responder Rate of 83% at One Hour; a Minimum of 35% of Subjects Met the Same ... |
| Nov 12, 2021 | AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response | Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development LAUSANNE, Switzerland, Nov. 12,... |
| Nov 12, 2021 | AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune Response | Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development LAUSANNE, Switzerland, Nov. 12,... |
| Nov 10, 2021 | AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease | Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo Ben... |
| Nov 8, 2021 | AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update | Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led b... |
| Nov 4, 2021 | AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases | LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its r... |
| Nov 3, 2021 | GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group | – Company advancing DuraLogic™ and ProGly™ platform chemistries which are poised to deliver the long-awaited promises of protein therapeutics for patients with autoimmune and metabolic diseases – – Proceeds to support key GRO platform devel... |
| Nov 2, 2021 | New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021 | LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigatio... |
| Nov 2, 2021 | New Data on AC Immune’s Abeta and pTau Clinical Programs in Alzheimer’s Disease To Be Presented at CTAD 2021 | LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigatio... |
| Oct 29, 2021 | AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors | Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading Swiss economist and former Vice President of t... |
| Oct 25, 2021 | AC Immune to Present at the Jefferies London Healthcare Conference | LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will part... |
| Oct 18, 2021 | Newron Pharmaceuticals S p A : Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB) | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing/Miscellaneous Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB) 18.10.2021 / 17:45 The issuer is solely responsible for the content o... |
| Sep 16, 2021 | Newron Pharmaceuticals S p A : announces Half-Year 2021 results | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year Report Newron announces Half-Year 2021 results 16.09.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Newron announces Half-Year 2021 resul... |
| Sep 6, 2021 | Newron Pharmaceuticals S p A : Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB) | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB) 06.09.2021 / 17:45 The issuer is solely responsible for the content of this an... |
| Sep 6, 2021 | Newron Pharmaceuticals S p A : Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia 06.09.2021 / 07:00 The issuer is solely responsible for the content of this announc... |
| Sep 3, 2021 | AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year | LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and C... |
| Aug 19, 2021 | Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology | Exclusive Worldwide Licensing Agreement with Cella Therapeutics Adds an Array of New Chemical Entities to Visus’ Drug Pipeline Agreement with DelSiTech for Sustained Drug Delivery Platform Allows Visus to Develop Next Generation Ophthalmic ... |
| Aug 10, 2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline Strengthens its Board of Direct... |
| Aug 10, 2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | All the sessions from Transform 2021 are available on-demand now. Watch now. Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activiti... |
| Aug 5, 2021 | Visus Therapeutics to Host First Capital Markets Day in New York City on August 31, 2021 | All the sessions from Transform 2021 are available on-demand now. Watch now. Company to provide overview of lead investigational asset, BRIMOCHOL™, for the treatment of presbyopia Will introduce expanded portfolio of new drug candidates tar... |
| Aug 5, 2021 | Visus Therapeutics to Host First Capital Markets Day in New York City on August 31, 2021 | Company to provide overview of lead investigational asset, BRIMOCHOL™, for the treatment of presbyopia Will introduce expanded portfolio of new drug candidates targeting an array of ophthalmic conditions SEATTLE–(BUSINESS WIRE)–August 5, 20... |
| Jul 27, 2021 | AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH | All-stock transaction maintains AC Immune’s strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune’s therapeutic development in Parkinson’s disease AC Im... |
| Jun 2, 2021 | Oncodisc : Inc. Acquired by PAVmed Digital Health Company Veris Health Inc. | WALNUT CREEK, Calif., June 2, 2021 /PRNewswire/ -- Oncodisc Inc. ("Oncodisc") today announced that it was acquired by Veris Health Inc ("Veris"), a majority owned digital health subsidiary of PAVmed Inc. ("PAVmed&qu... |
| May 26, 2021 | QurAlis Boosts World-Class Leadership Team With Addition of Three New Members | Vikas Sharma, Ph.D., Shirley Lasch, and Tim O’Brien join team dedicated to developing new treatments for ALS and other genetically validated neurodegenerative diseases |
| May 20, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA 20.05.2021 / 07:00 The issuer is solely responsible for the content of this announcement.... |
| May 12, 2021 | Juno Diagnostics Announces Closing of $25 Million Series A Financing Led by Perceptive Xontogeny Venture Fund | Join Transform 2021 this July 12-16. Register for the AI event of the year. – Reproductive health pioneers developing genetic testing solutions to dramatically improve access to prenatal care for all women in all geographies – – Experienced... |
| May 12, 2021 | Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP | – PXV Fund II plans to lead Series A financings in 10 to 12 early-stage life sciences companies – – PXV Funds total $725 million of AUMs since launching strategy less than 18 months ago – NEW YORK & BOSTON–(BUSINESS WIRE)–May 12, 2021– ... |
| May 12, 2021 | Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies | – Five new drug therapeutic companies supported with strategic and operational guidance and seed capital – – Programs include a diverse portfolio of therapeutic modalities across a wide range of disease areas – BOSTON–(BUSINESS WIRE)–May 12... |
| May 12, 2021 | Juno Diagnostics Announces Closing of $25 Million Series A Financing Led by Perceptive Xontogeny Venture Fund | – Reproductive health pioneers developing genetic testing solutions to dramatically improve access to prenatal care for all women in all geographies – – Experienced leadership team developed and launched the industry’s first noninvasive pre... |
| May 12, 2021 | Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP | Join Transform 2021 this July 12-16. Register for the AI event of the year. – PXV Fund II plans to lead Series A financings in 10 to 12 early-stage life sciences companies – – PXV Funds total $725 million of AUMs since launching strategy le... |
| May 12, 2021 | Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies | Join Transform 2021 this July 12-16. Register for the AI event of the year. – Five new drug therapeutic companies supported with strategic and operational guidance and seed capital – – Programs include a diverse portfolio of therapeutic mod... |
| May 4, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA 04-May-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR ... |
| May 4, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron announces Paragraph IV ANDA filing for Xadago(R) (safinamide) in the USA 04.05.2021 / 07:00 The issuer is solely responsible for the content of this announcement. ... |
| Apr 14, 2021 | TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists | DENVER, and CHICAGO, APRIL 14, 2021 –TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced data presented at the American Association o... |
| Apr 13, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces AGM 2021 result | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): AGM/EGM Newron announces AGM 2021 result 13.04.2021 / 12:00 The issuer is solely responsible for the content of this announcement. Newron announces AGM 2021 result Milan, Italy - April... |
| Apr 13, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces AGM 2021 result | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous Newron announces AGM 2021 result 13-Apr-2021 / 12:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the conten... |
| Apr 8, 2021 | TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors | HOUSTON, DENVER, and CHICAGO, APRIL 8, 2021 – The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumor... |
| Apr 8, 2021 | TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors | Studies to evaluate liver and pancreatic cancers with SD-101, an investigational TLR9 agonist, in combination with checkpoint inhibition immunotherapy Studies to deliver investigational SD-101 directly to the site of the disease employing n... |
| Apr 1, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia | DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia 01.04.2021 / 07:00 The issuer is solely responsible f... |
| Apr 1, 2021 | NEWRON PHARMACEUTICALS S.P.A. Newron Pharmaceuticals S p A : announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia | EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Miscellaneous Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia 01-Apr-2021 / 07:00 CET/CEST Release of an ad hoc... |
| Mar 31, 2021 | AC IMMUNE SA AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease | LAUSANNE, Switzerland, March 31, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss t... |
| Mar 16, 2021 | AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine | Topline ACI-24 Phase 1b immunogenicity and safety results reported today at a global Down syndrome symposium Reported new data in non-human primates for optimized vaccine formulation which shows strong response against key pathological Abet... |
| Mar 10, 2021 | TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results | AUSTIN, Texas--(BUSINESS WIRE)--Mar 10, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing ... |
| Mar 9, 2021 | AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases | Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43 First biologically active small molecule inhibitors of intracellular ... |
| Mar 9, 2021 | NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration | RADNOR, Pa. & AUSTIN, Texas--(BUSINESS WIRE)--Mar 9, 2021-- NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreem... |
| Mar 9, 2021 | Feasibility Arrangement for Shelf-stable Powder Form of Messenger RNA COVID-19 Vaccine Candidate Announced by GreenLight Biosciences and TFF Pharmaceuticals | MEDFORD, Mass. & AUSTIN, Texas--(BUSINESS WIRE)--Mar 9, 2021-- GreenLight Biosciences, Inc., a privately-held RNA vaccine developer and manufacturer, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical compa... |
| Mar 4, 2021 | TFF Pharmaceuticals Provides Update on Clinical Development Programs | AUSTIN, Texas--(BUSINESS WIRE)--Mar 4, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (... |
| Feb 24, 2021 | TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call on March 10, 2021 | AUSTIN, Texas--(BUSINESS WIRE)--Feb 24, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing ... |
| Feb 24, 2021 | AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference | LAUSANNE, Switzerland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that four new data pr... |
| Feb 23, 2021 | SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids | Joining forces to develop gene therapies for multiple life-threatening disorders MUNICH–(BUSINESS WIRE)–February 23, 2021– SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, ann... |
Show more
Reviews 0
FAQ about LaVoieHealthScience
When was LaVoieHealthScience founded?
LaVoieHealthScience was founded in 2001.
What has the press written about LaVoieHealthScience?
Parsers VC has collected 196 articles mentioning LaVoieHealthScience, among them “Deciphex Secures $32.3M Series C to Address Global Pathology Shortage” (Jan 7, 2025) and “Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines” (Dec 12, 2024).
Is LaVoieHealthScience still active?
Yes, LaVoieHealthScience is active; its latest activity on Parsers VC dates from Jun 2, 2025.